Valuation: Verastem, Inc.

Market Cap 51Cr 44Cr 41Cr 38Cr 71Cr 4.87TCr 73Cr 486.1Cr 190.78Cr 2.42TCr 191.41Cr 187.21Cr 8.12TCr P/E 2026 *
-3.66x
P/E 2027 * -5.17x
Enterprise Value 34Cr 30Cr 28Cr 26Cr 48Cr 3.29TCr 49Cr 328.73Cr 129.02Cr 1.64TCr 129.44Cr 126.6Cr 5.49TCr EV / Sales 2026 *
3.38x
EV / Sales 2027 * 1.68x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-4.92%
1 week-4.13%
1 month+51.83%
3 months+6.23%
6 months-4.92%
Current year-24.87%
1 week 5.54
Extreme 5.54
6.46
1 month 4.07
Extreme 4.07
6.46
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
21/05/26 Free

Director

36,000 0.0410%
21/05/26 Free

Director

36,000 0.0410%
21/05/26 Free

Chairman

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-4.92%-4.13%-6.00%-47.56% 51Cr
+2.35%+2.74%+33.41%+79.20% 5.65TCr
-0.21%-7.38%+25.34%+63.02% 5.36TCr
-2.44%+1.40%-15.74%-16.80% 2.29TCr
-2.85%-7.78%-8.09%+346.36% 2.14TCr
+2.49%-0.92%+20.31%-12.15% 2.03TCr
+0.79%-1.06%+29.29%-33.32% 1.76TCr
+0.58%-5.88%+16.30%+540.37% 1.47TCr
-5.25%-4.23%+46.41%+169.05% 1.33TCr
+3.41%-6.61%+163.08%+280.43% 1.35TCr
Average -0.61%-3.83%+30.43%+136.86% 2.34TCr
Weighted average by Cap. +0.22%-2.96%+28.60%+119.62%

Financials

2026 *2027 *
Net sales 10Cr 8.86Cr 8.24Cr 7.57Cr 14Cr 972.47Cr 15Cr 97Cr 38Cr 484.14Cr 38Cr 37Cr 1.62TCr 18Cr 16Cr 14Cr 13Cr 25Cr 1.7TCr 25Cr 170.1Cr 67Cr 847.59Cr 67Cr 66Cr 2.84TCr
Net income -17Cr -14Cr -13Cr -12Cr -23Cr -1.58TCr -24Cr -157.87Cr -62Cr -786.65Cr -62Cr -61Cr -2.64TCr -14Cr -12Cr -11Cr -11Cr -20Cr -1.36TCr -20Cr -135.49Cr -53Cr -675.15Cr -53Cr -52Cr -2.26TCr
Net Debt -16Cr -14Cr -13Cr -12Cr -23Cr -1.58TCr -24Cr -157.37Cr -62Cr -784.15Cr -62Cr -61Cr -2.63TCr -21Cr -18Cr -17Cr -16Cr -29Cr -2TCr -30Cr -199.91Cr -78Cr -996.11Cr -79Cr -77Cr -3.34TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
31/26/31 $5.800 -4.92% 18,57,262
30/26/30 $6.100 +1.50% 14,51,955
29/26/29 $6.010 -3.53% 22,49,888
28/26/28 $6.230 +2.47% 12,75,019
27/26/27 $6.080 +0.50% 22,44,215
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.800USD
Average target price
15.00USD
Spread / Average Target
+158.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock